SLT is the sensible option

Article

Selective laser trabeculoplasty (SLT) should be used before alteration of treatment or trabeculectomy, according to the findings of a study conducted by Bharat Kapoor and a team of colleagues from the UK.

Selective laser trabeculoplasty (SLT) should be used before alteration of treatment or trabeculectomy, according to the findings of a study conducted by Bharat Kapoor and a team of colleagues from the UK.

The team conducted a retrospective analysis of case notes in order to evaluate the success rate, duration of success and the factors that influence the outcome of SLT in patients with open angle glaucoma and ocular hypertension (OHT) uncontrolled on maximum tolerated medical treatment (MTMT). A total of 88 case notes (155 eyes) were reviewed with success being defined as a reduction in intraocular pressure (IOP) of 20% from baseline. Patients showing no response up to three months following treatment were classified as non-responders.

The average number of topical medication drops per patient prior to SLT was 1.86. A total of 92% of eyes responded to SLT treatment and, of these, 88% achieved target IOP by month 12. Target IOP was reached by 69% at two years, 36.8% at three years, 20.8% at four years and 18% at five years. Those patients using prostaglandin analogues prior to SLT demonstrated an average duration of success of 29 months compared with 31 months for patients not using the analogues. A significant number of patients were able to stop using eye drops following the treatment.

Kapoor and colleagues recommended that SLT should be used before alteration of treatment or trabeculectomy. It is able to omit patient compliance factor whilst also reducing the cost burden of additional topical medication. In addition to these factors, it is also a repeatable procedure since it does not damage the trabecular meshwork.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.